BMRN

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +6% above

+ Price vs 50-day avg +8% above

◦ RSI (14) 62 · neutral

+ MACD trend positive

◦ 52-week position 57% · mid-range

Sentiment · smart money Bearish

◦ Trend (MA cross) 50d $55 › 200d $56 — 200d above 50d

+ Institutional flow 4 of 556 funds reported for Jun 30 · net +1.8K sh shares

− Insider flow Net -$176.7K over 90 days · 100% sells

− Short interest 6.48% of float · ▲ +7.9% MoM · 6.1 days cover

◦ Volume signal Volume near normal

◦ Institution breadth 556 holders — mid 3-yr range

Fundamentals Strong

+ Revenue growth +18% Y/Y

− EPS growth −19% Y/Y

+ Free cash flow $725.0M

− Valuation P/E 42.4 · rich

+ Balance sheet net cash $714.5M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 2, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 4, 2026

Total Revenues · full-year 2026 Initiated $3.83B – $3.93B

prior FY $3.22B midpoint +20.3% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+6% above Bullish

Price vs 50-day avg

+8% above Bullish

RSI (14)

62 · neutral Neutral

MACD trend

positive Bullish

52-week position

57% · mid-range Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $55 › 200d $56 — 200d above 50d

Institutional flow Accumulating

4 of 556 funds reported for Jun 30 · net +1.8K sh shares

Insider flow Distributing

Net -$176.7K over 90 days · 100% sells

Short interest Rising

6.48% of float · ▲ +7.9% MoM · 6.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

556 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $49 Now $59 · 57% 52-wk high $66

vs 200-day avg +6% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Operating cash flows	$828M	full year 2025	—
Total cash and investments	2B	year-end 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BMRN Biomarin Pharmaceutical Inc this stock	$11.40B	-0.7%	+17.6%	42.4	6.5%
AKTX Akari Therapeutics Plc	$953.21B	-9.9%	—	—	0.0%
ONC BeOne Medicines Ltd.	$470.30B	-2.0%	+22179.2%	957.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.02B	+16.5%	+46.2%	31.3	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.80B	-15.1%	+20.8%	16.3	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

556

% held: 92.1%
Reported: 4 of 556
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

496

View

Short & Settlement

Short Interest Rising

Shares short

12.5M

Days to cover: 6.1d
Change: +911.2K sh

View

Short Volume

Short vol %

39%

As of: Jul 2, 2026

Short Total

View

Fails to Deliver

FTD shares

114

Value: $6.3K
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

41.9%

Week of: Jun 15, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$176.7K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Mar 6, 2023

View

Financials

Revenue (FY)

$3.2B

Net income (FY): $348.9M
EPS diluted: $1.80

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 4, 2026
This year: 13

View

Proposed Sales

Value

$176.7K

Shares: 3.3K
Filed: May 7, 2026

View

Earnings & Events

Earnings Calls

Last call

May 4, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
BMRN	+2.9%	+7.9%	-2.3%	+3.1%	-0.7%
SPY	+1.4%	-1.3%	+8.0%	-0.3%	+9.2%
vs SPY	+1.4%	+9.2%	-10.3%	+3.4%	-10.0%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance